drugset / Trial / NCT01009242
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate
RandomizedParallel-groupDouble-blindBasic science
Summary
The primary objectives are to determine the relationship between blood levels of CDP6038 and suppression of C-reactive Protein (CRP) following single doses given as intravenous (IV) infusion or subcutaneous (SC) injection to Rheumatoid Arthritis (RA) patients. The safety of CDP6038 will also be evaluated.
Timeline
- Start
- 2009-10
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olokizumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Olokizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Background | Methotrexate | Small molecule | — | — |